10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Activatable polymer nanoagonist for second near-infrared photothermal immunotherapy of cancer

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Nanomedicine in combination with immunotherapy offers opportunities to treat cancer in a safe and effective manner; however, remote control of immune response with spatiotemporal precision remains challenging. We herein report a photothermally activatable polymeric pro-nanoagonist (APNA) that is specifically regulated by deep-tissue-penetrating second near-infrared (NIR-II) light for combinational photothermal immunotherapy. APNA is constructed from covalent conjugation of an immunostimulant onto a NIR-II semiconducting transducer through a labile thermo-responsive linker. Upon NIR-II photoirradiation, APNA mediates photothermal effect, which not only triggers tumor ablation and immunogenic cell death but also initiates the cleavage of thermolabile linker to liberate caged agonist for in-situ immune activation in deep solid tumor (8 mm). Such controlled immune regulation potentiates systemic antitumor immunity, leading to promoted cytotoxic T lymphocytes and helper T cell infiltration in distal tumor, lung and liver to inhibit cancer metastasis. Thereby, the present work illustrates a generic strategy to prepare pro-immunostimulants for spatiotemporal regulation of cancer nano-immunotherapy.

          Abstract

          Precise control of immune response remains challenging for cancer immunotherapy. Here, the authors report on photothermally activatable semiconducting polymeric pro-agonist in response to second near-infrared window light for regulated photothermal immunotherapy.

          Related collections

          Most cited references52

          • Record: found
          • Abstract: not found
          • Article: not found

          Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Dendritic cells in cancer immunology and immunotherapy

            Dendritic cells (DCs) are a diverse group of specialized antigen-presenting cells with key roles in the initiation and regulation of innate and adaptive immune responses. As such, there is currently much interest in modulating DC function to improve cancer immunotherapy. Many strategies have been developed to target DCs in cancer, such as the administration of antigens with immunomodulators that mobilize and activate endogenous DCs, as well as the generation of DC-based vaccines. A better understanding of the diversity and functions of DC subsets and of how these are shaped by the tumour microenvironment could lead to improved therapies for cancer. Here we will outline how different DC subsets influence immunity and tolerance in cancer settings and discuss the implications for both established cancer treatments and novel immunotherapy strategies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Nanocarriers as an emerging platform for cancer therapy.

              Nanotechnology has the potential to revolutionize cancer diagnosis and therapy. Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients. Several therapeutic nanocarriers have been approved for clinical use. However, to date, there are only a few clinically approved nanocarriers that incorporate molecules to selectively bind and target cancer cells. This review examines some of the approved formulations and discusses the challenges in translating basic research to the clinic. We detail the arsenal of nanocarriers and molecules available for selective tumour targeting, and emphasize the challenges in cancer treatment.
                Bookmark

                Author and article information

                Contributors
                kypu@ntu.edu.sg
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                2 February 2021
                2 February 2021
                2021
                : 12
                : 742
                Affiliations
                [1 ]GRID grid.59025.3b, ISNI 0000 0001 2224 0361, School of Chemical and Biomedical Engineering, , Nanyang Technological University, ; Singapore, Singapore
                [2 ]GRID grid.59025.3b, ISNI 0000 0001 2224 0361, Division of Chemistry and Biological Chemistry, School of Physical and Mathematical Sciences, , Nanyang Technological University, ; Singapore, Singapore
                Author information
                http://orcid.org/0000-0002-8064-6009
                Article
                21047
                10.1038/s41467-021-21047-0
                7854754
                33531498
                1d09d75f-a904-4f10-a94d-baac8f9f977b
                © The Author(s) 2021

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 29 May 2020
                : 7 January 2021
                Categories
                Article
                Custom metadata
                © The Author(s) 2021

                Uncategorized
                drug delivery,nanotechnology in cancer
                Uncategorized
                drug delivery, nanotechnology in cancer

                Comments

                Comment on this article